BIOMAT Database Logo BIOMAT Database Logo

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. 2020

Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Saclay, Villejuif, France.

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

UI MeSH Term Description Entries

Related Publications

Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer.
June 2021, Biomedicines,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
June 2012, Current treatment options in oncology,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
February 2014, Future oncology (London, England),
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.
November 2023, Clinical cancer research : an official journal of the American Association for Cancer Research,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
June 2021, Prostate cancer and prostatic diseases,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
January 2021, Frontiers in oncology,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer.
January 2021, Frontiers in oncology,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
[New generation of androgen receptor antagonist in castration resistant prostate cancer].
December 2014, Nihon rinsho. Japanese journal of clinical medicine,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
March 2019, European urology,
Pernelle Lavaud, and Clément Dumont, and Constance Thibault, and Laurence Albiges, and Giulia Baciarello, and Emeline Colomba, and Ronan Flippot, and Alina Fuerea, and Yohann Loriot, and Karim Fizazi
A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
October 2020, Clinical genitourinary cancer,
Copied contents to your clipboard!